Surrozen Inc (SRZN) News & EventsSRZNSurrozen Inc

Surrozen's SZN-8141 IND Application Approved, Expected to Raise $95.1M

Surrozen announced its Investigational New Drug, IND, application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema, DME. The FDA clearance of the SZN-8141 IND satisfies the second closing milestone under Surrozen's March 2025 two-tranche private placement. Subject to the terms and conditions of the securities purchase agreement, the second closing is expected to provide approximately $95.1M in gross proceeds to Surrozen, before deducting placement agent fees and other expenses. The second closing is expected to occur on or about October 20, 2026, subject to satisfaction of the applicable closing conditions.

Surrozen Submits New Drug Application for SZN-8141 to FDA

Surrozen announced the submission of an investigational new drug application to the FDA seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody, for the treatment of diabetic macular edema.

Surrozen Q1 Revenue Hits $5M, Exceeds Consensus

Reports Q1 revenue $5M, consensus $4M. The company said, "Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen's pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs."